[
    [
        {
            "time": "",
            "original_text": "复星医药：董事会会议审议通过关于受让重庆复创医药研究有限公司23.9992%股权的议案",
            "features": {
                "keywords": [
                    "复星医药",
                    "重庆复创",
                    "股权受让",
                    "董事会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：董事会会议审议通过关于受让重庆复创医药研究有限公司23.9992%股权的议案",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药产业拟出资1.41亿美元增持重庆复创24%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "重庆复创",
                    "增资",
                    "股权增持"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药产业拟出资1.41亿美元增持重庆复创24%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196.SH)：子公司拟以1.41亿美元受让重庆复创23.9992%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "重庆复创",
                    "股权受让",
                    "子公司"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：子公司拟以1.41亿美元受让重庆复创23.9992%股权",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药(600196.SH)子公司拟1.41亿美元受让小分子靶向药物企业重庆复创24%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "重庆复创",
                    "小分子靶向药物",
                    "股权受让"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药(600196.SH)子公司拟1.41亿美元受让小分子靶向药物企业重庆复创24%股权",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "复星医药5500万打水漂 终止引进的SGLT-2抑制剂开发",
            "features": {
                "keywords": [
                    "复星医药",
                    "SGLT-2抑制剂",
                    "项目终止",
                    "研发投入"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药5500万打水漂 终止引进的SGLT-2抑制剂开发",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        }
    ]
]